Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters
BACKGROUND: Dynamic changes in Human Immunodeficiency Virus 1 (HIV-1) sequence diversity and divergence are associated with immune control during primary infection and progression to AIDS. Consensus sequencing or single genome amplification sequencing of the HIV-1 envelope (env) gene, in particular...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605130/ https://www.ncbi.nlm.nih.gov/pubmed/23331949 http://dx.doi.org/10.1186/1742-4690-10-8 |
_version_ | 1782263826633195520 |
---|---|
author | Gall, Astrid Kaye, Steve Hué, Stéphane Bonsall, David Rance, Richard Baillie, Gregory J Fidler, Sarah J Weber, Jonathan N McClure, Myra O Kellam, Paul |
author_facet | Gall, Astrid Kaye, Steve Hué, Stéphane Bonsall, David Rance, Richard Baillie, Gregory J Fidler, Sarah J Weber, Jonathan N McClure, Myra O Kellam, Paul |
author_sort | Gall, Astrid |
collection | PubMed |
description | BACKGROUND: Dynamic changes in Human Immunodeficiency Virus 1 (HIV-1) sequence diversity and divergence are associated with immune control during primary infection and progression to AIDS. Consensus sequencing or single genome amplification sequencing of the HIV-1 envelope (env) gene, in particular the variable (V) regions, is used as a marker for HIV-1 genome diversity, but population diversity is only minimally, or semi-quantitatively sampled using these methods. RESULTS: Here we use second generation deep sequencing to determine inter-and intra-patient sequence heterogeneity and to quantify minor variants in a cohort of individuals either receiving or not receiving antiretroviral treatment following seroconversion; the SPARTAC trial. We show, through a cross-sectional study of sequence diversity of the env V3 in 30 antiretroviral-naive patients during primary infection that considerable population structure diversity exists, with some individuals exhibiting highly constrained plasma virus diversity. Diversity was independent of clinical markers (viral load, time from seroconversion, CD4 cell count) of infection. Serial sampling over 60 weeks of non-treated individuals that define three initially different diversity profiles showed that complex patterns of continuing HIV-1 sequence diversification and divergence could be readily detected. Evidence for minor sequence turnover, emergence of new variants and re-emergence of archived variants could be inferred from this analysis. Analysis of viral divergence over the same time period in patients who received short (12 weeks, ART12) or long course antiretroviral therapy (48 weeks, ART48) and a non-treated control group revealed that ART48 successfully suppressed viral divergence while ART12 did not have a significant effect. CONCLUSIONS: Deep sequencing is a sensitive and reliable method for investigating the diversity of the env V3 as an important component of HIV-1 genome diversity. Detailed insights into the complex early intra-patient dynamics of env V3 diversity and divergence were explored in antiretroviral-naïve recent seroconverters. Long course antiretroviral therapy, initiated soon after seroconversion and administered for 48 weeks, restricts HIV-1 divergence significantly. The effect of ART12 and ART48 on clinical markers of HIV infection and progression is currently investigated in the SPARTAC trial. |
format | Online Article Text |
id | pubmed-3605130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36051302013-03-26 Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters Gall, Astrid Kaye, Steve Hué, Stéphane Bonsall, David Rance, Richard Baillie, Gregory J Fidler, Sarah J Weber, Jonathan N McClure, Myra O Kellam, Paul Retrovirology Research BACKGROUND: Dynamic changes in Human Immunodeficiency Virus 1 (HIV-1) sequence diversity and divergence are associated with immune control during primary infection and progression to AIDS. Consensus sequencing or single genome amplification sequencing of the HIV-1 envelope (env) gene, in particular the variable (V) regions, is used as a marker for HIV-1 genome diversity, but population diversity is only minimally, or semi-quantitatively sampled using these methods. RESULTS: Here we use second generation deep sequencing to determine inter-and intra-patient sequence heterogeneity and to quantify minor variants in a cohort of individuals either receiving or not receiving antiretroviral treatment following seroconversion; the SPARTAC trial. We show, through a cross-sectional study of sequence diversity of the env V3 in 30 antiretroviral-naive patients during primary infection that considerable population structure diversity exists, with some individuals exhibiting highly constrained plasma virus diversity. Diversity was independent of clinical markers (viral load, time from seroconversion, CD4 cell count) of infection. Serial sampling over 60 weeks of non-treated individuals that define three initially different diversity profiles showed that complex patterns of continuing HIV-1 sequence diversification and divergence could be readily detected. Evidence for minor sequence turnover, emergence of new variants and re-emergence of archived variants could be inferred from this analysis. Analysis of viral divergence over the same time period in patients who received short (12 weeks, ART12) or long course antiretroviral therapy (48 weeks, ART48) and a non-treated control group revealed that ART48 successfully suppressed viral divergence while ART12 did not have a significant effect. CONCLUSIONS: Deep sequencing is a sensitive and reliable method for investigating the diversity of the env V3 as an important component of HIV-1 genome diversity. Detailed insights into the complex early intra-patient dynamics of env V3 diversity and divergence were explored in antiretroviral-naïve recent seroconverters. Long course antiretroviral therapy, initiated soon after seroconversion and administered for 48 weeks, restricts HIV-1 divergence significantly. The effect of ART12 and ART48 on clinical markers of HIV infection and progression is currently investigated in the SPARTAC trial. BioMed Central 2013-01-18 /pmc/articles/PMC3605130/ /pubmed/23331949 http://dx.doi.org/10.1186/1742-4690-10-8 Text en Copyright ©2013 Gall et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Gall, Astrid Kaye, Steve Hué, Stéphane Bonsall, David Rance, Richard Baillie, Gregory J Fidler, Sarah J Weber, Jonathan N McClure, Myra O Kellam, Paul Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters |
title | Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters |
title_full | Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters |
title_fullStr | Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters |
title_full_unstemmed | Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters |
title_short | Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters |
title_sort | restriction of v3 region sequence divergence in the hiv-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605130/ https://www.ncbi.nlm.nih.gov/pubmed/23331949 http://dx.doi.org/10.1186/1742-4690-10-8 |
work_keys_str_mv | AT gallastrid restrictionofv3regionsequencedivergenceinthehiv1envelopegeneduringantiretroviraltreatmentinacohortofrecentseroconverters AT kayesteve restrictionofv3regionsequencedivergenceinthehiv1envelopegeneduringantiretroviraltreatmentinacohortofrecentseroconverters AT huestephane restrictionofv3regionsequencedivergenceinthehiv1envelopegeneduringantiretroviraltreatmentinacohortofrecentseroconverters AT bonsalldavid restrictionofv3regionsequencedivergenceinthehiv1envelopegeneduringantiretroviraltreatmentinacohortofrecentseroconverters AT rancerichard restrictionofv3regionsequencedivergenceinthehiv1envelopegeneduringantiretroviraltreatmentinacohortofrecentseroconverters AT bailliegregoryj restrictionofv3regionsequencedivergenceinthehiv1envelopegeneduringantiretroviraltreatmentinacohortofrecentseroconverters AT fidlersarahj restrictionofv3regionsequencedivergenceinthehiv1envelopegeneduringantiretroviraltreatmentinacohortofrecentseroconverters AT weberjonathann restrictionofv3regionsequencedivergenceinthehiv1envelopegeneduringantiretroviraltreatmentinacohortofrecentseroconverters AT mccluremyrao restrictionofv3regionsequencedivergenceinthehiv1envelopegeneduringantiretroviraltreatmentinacohortofrecentseroconverters AT kellampaul restrictionofv3regionsequencedivergenceinthehiv1envelopegeneduringantiretroviraltreatmentinacohortofrecentseroconverters |